ketoconazole has been researched along with Hormone-Dependent Neoplasms in 17 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The growth-inhibitory effects of ketoconazole, an antifungal agent which inhibits arachidonic acid lipoxygenases and cytochrome P-450 enzymes, were tested in human colon and breast cancer cell lines." | 3.68 | Effects of ketoconazole on the proliferation and cell cycle of human cancer cell lines. ( Coudray, AM; Fagot, D; Forgue-Lafitte, ME; Mester, J, 1992) |
| "Twenty-two patients who had progressive metastatic prostatic carcinoma (Stage D2) despite androgen-deprivation therapy (bilateral orchiectomy, 10 cases; bilateral orchiectomy followed by diethylstilbestrol, 7 cases; diethylstilbestrol, 3 cases; combined megestrol acetate and low-dose estrogen, 2 cases) were treated with ketoconazole." | 3.67 | Ketoconazole therapy for hormonally refractive metastatic prostate cancer. ( Babaian, RJ; Johnson, DE; Tenney, D; von Eschenbach, AC; Wishnow, KI, 1988) |
| "Mitoxantrone has activity similar to that of doxorubicin, is less cardiotoxic, and is widely used to treat prostate cancer." | 2.72 | Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer. ( Bergan, RC; Eklund, J; Gallot, L; Jovanovic, B; Kozloff, M; Mariott, M; Pins, M; Robin, E; Schilder, L; Starr, A; Vlamakis, J, 2006) |
| "We report the case of a patient with prostate cancer who develops mediastinal lymphadenopathy, pulmonary nodules and cutaneous metastases 8 years after the diagnosis." | 1.34 | [Mediastinal lymph nodes during the course of a metastatic prostate cancer]. ( Aguilera Tubet, C; Ballestero Diego, R; Roca Edreira, A; Villanueva Peña, A; Zubillaga Guerrero, S, 2007) |
| "For example, androgen-independent prostate cancer cells, DU-145 and PC-3, are relatively insensitive to the anti-proliferative action of 1,25-(OH)(2)D(3)." | 1.33 | Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. ( Campbell, MJ; Simons, C; Yee, SW, 2006) |
| "The median time to disease progression or dose escalation on LDK was 3." | 1.33 | Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. ( Jackman, DM; Kantoff, PW; Nakabayashi, M; Oh, WK; Regan, MM; Xie, W, 2006) |
| "Ketoconazole is a potent inhibitor of the P450 series of enzymes that are essential for the production of androgens." | 1.27 | The effects of ketoconazole on testosterone production and normal and malignant androgen dependent tissues of the adult rat. ( Trachtenberg, J, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (23.53) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Frotscher, M | 1 |
| Ziegler, E | 1 |
| Marchais-Oberwinkler, S | 1 |
| Kruchten, P | 1 |
| Neugebauer, A | 1 |
| Fetzer, L | 1 |
| Scherer, C | 1 |
| Müller-Vieira, U | 1 |
| Messinger, J | 1 |
| Thole, H | 1 |
| Hartmann, RW | 2 |
| Hu, Q | 1 |
| Yin, L | 1 |
| Jagusch, C | 1 |
| Hille, UE | 1 |
| Miller, K | 1 |
| Millikan, R | 1 |
| Thall, PF | 1 |
| Lee, SJ | 1 |
| Jones, D | 1 |
| Cannon, MW | 1 |
| Kuebler, JP | 1 |
| Wade, J | 1 |
| Logothetis, CJ | 1 |
| Scholz, M | 1 |
| Jennrich, R | 1 |
| Strum, S | 1 |
| Brosman, S | 1 |
| Johnson, H | 1 |
| Lam, R | 1 |
| Yee, SW | 1 |
| Campbell, MJ | 1 |
| Simons, C | 1 |
| Eklund, J | 1 |
| Kozloff, M | 1 |
| Vlamakis, J | 1 |
| Starr, A | 1 |
| Mariott, M | 1 |
| Gallot, L | 1 |
| Jovanovic, B | 1 |
| Schilder, L | 1 |
| Robin, E | 1 |
| Pins, M | 1 |
| Bergan, RC | 1 |
| Nakabayashi, M | 1 |
| Xie, W | 1 |
| Regan, MM | 1 |
| Jackman, DM | 1 |
| Kantoff, PW | 1 |
| Oh, WK | 1 |
| Roca Edreira, A | 1 |
| Aguilera Tubet, C | 1 |
| Villanueva Peña, A | 1 |
| Ballestero Diego, R | 1 |
| Zubillaga Guerrero, S | 1 |
| Trachtenberg, J | 2 |
| Bare, RL | 1 |
| Torti, FM | 1 |
| Long, BJ | 1 |
| Grigoryev, DN | 1 |
| Nnane, IP | 1 |
| Liu, Y | 1 |
| Ling, YZ | 1 |
| Brodie, AM | 1 |
| Forgue-Lafitte, ME | 1 |
| Coudray, AM | 1 |
| Fagot, D | 1 |
| Mester, J | 1 |
| Huben, RP | 1 |
| Eichenberger, T | 1 |
| Johnson, DE | 1 |
| Babaian, RJ | 1 |
| von Eschenbach, AC | 1 |
| Wishnow, KI | 1 |
| Tenney, D | 1 |
| Namer, M | 1 |
| Boublil, JL | 1 |
| Kather, R | 1 |
| Cavaglione, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase II Trial of Taxol/VP-16/Estramustine vs. Ketoconazole/Doxorubicin/Vinblastine/Estramustine in Androgen Independent Prostate Cancer[NCT00003084] | Phase 2 | 75 participants (Actual) | Interventional | 1997-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for ketoconazole and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
[Castration resistant prostate cancer 2011].
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormo | 2011 |
Endocrine therapy of prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aminoglutethimide; Androgen Antagonists; Antineoplasti | 1998 |
3 trials available for ketoconazole and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin | 2003 |
Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Ketoconazole; Male; | 2006 |
Hormone therapy of prostatic bone metastases.
Topics: Actuarial Analysis; Androgen Antagonists; Bone Neoplasms; Combined Modality Therapy; Diethylstilbest | 1992 |
12 other studies available for ketoconazole and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent disease
Topics: 17-Hydroxysteroid Dehydrogenases; Animals; Aryl Hydrocarbon Hydroxylases; Binding Sites; Caco-2 Cell | 2008 |
Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.
Topics: Antineoplastic Agents, Hormonal; Biphenyl Compounds; Enzyme Inhibitors; Humans; Inhibitory Concentra | 2010 |
Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.
Topics: Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; | 2005 |
Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells.
Topics: Androgens; Animals; Cell Cycle Proteins; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; | 2006 |
Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Disease Progress | 2006 |
[Mediastinal lymph nodes during the course of a metastatic prostate cancer].
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bon | 2007 |
The effects of ketoconazole on testosterone production and normal and malignant androgen dependent tissues of the adult rat.
Topics: Adenocarcinoma; Animals; Castration; Depression, Chemical; Gonadotropin-Releasing Hormone; Half-Life | 1984 |
Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androgen Receptor Antagonists; Androstadienes; A | 2000 |
Effects of ketoconazole on the proliferation and cell cycle of human cancer cell lines.
Topics: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; Adenocarcinoma; Breast Neoplasms; Cell | 1992 |
Effects of high-dose ketoconazole in patients with androgen-independent prostatic cancer.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Alkaline Phosphatase; Humans; Ketoconazole; Male; Middle | 1988 |
Ketoconazole therapy for hormonally refractive metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Bone Neoplasms; Carcinoma; Combined Modality Therapy; Diethylsti | 1988 |
[Cancer of the prostate: new hormone therapies].
Topics: Androgen Antagonists; Cyproterone; Flutamide; Humans; Ketoconazole; Male; Medroxyprogesterone; Meges | 1986 |